Search
for
Sort by
Research 871–900 of 1000+
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- 1325 Age-dependent loss of the stemness and antimicrobial defense function of dermal fibroblasts is mediated by TGFbeta
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- TNF inhibitor induced alopecia: an unusual form of psoriasiform alopecia that breaks the Renbök mold
- THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
- Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
- Enhanced Insights into Frontal Fibrosing Alopecia: Advancements in Pathogenesis Understanding and Management Strategies
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- Update: baricitinib for alopecia areata
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Alopecia areata
- Ritlecitinib: First Approval
- Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction
- Topical tofacitinib in treatment of alopecia areata
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
- Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
- Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
- Dermoscopy — 4th Conference of the Section of Dermoscopy and Other Skin Imaging Techniques (DiTOS) of the Polish Dermatological Society — Abstracts
- The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
- Modern Management Approaches for Alopecia Areata
- What’s new in the treatment of hair loss?
- MicroRNA-1246 Inhibits NFATc1 Phosphorylation and Regulates T Helper 17 Cell Activation in the Pathogenesis of Severe Alopecia Areata
- BH03: Systemic sclerosis and frontal fibrosing alopecia: a novel combination of scarring alopecia
- Roles of tumor suppressors in regulating tumor-associated inflammation
- Mesenchymal Stem Cells Antagonize IFN-Induced Proinflammatory Changes and Growth Inhibition Effects via Wnt/β-Catenin and JAK/STAT Pathway in Human Outer Root Sheath Cells and Hair Follicles